Skip to main content
Premium Trial:

Request an Annual Quote

Pressure Biosciences Q3 Revenues Fall 8 Percent

NEW YORK (GenomeWeb) – Pressure Biosciences reported yesterday a nearly 8 percent drop in third quarter revenues as increased instrument sales failed to offset a decline in grant revenues.

For the three-month period ended Sept. 30, Pressure's revenues fell to $535,334 from $580,334 in the same quarter last year. Instrument sales were up nearly 13 percent to $383,789 from $340,084 a year ago, but the increase was  more than offset by a decline in grant revenues to $34,385 from $98,882.

Pressure's Q3 net loss grew to $945,207, or $.03 per share, from a year-ago net loss of $657,928, or $.03 per share. Shares used to calculate the loss per share in the third quarter 2016 were approximately 29.4 million, compared with roughly 20.7 million in the same quarter last year.

R&D spending in the quarter fell to $268,317 from $355,574. The year-ago figure includes the cost of research performed by a customer on Pressure's behalf. SG&A costs, meanwhile, shrank 35 percent to $455,930 from $705,684.

At the end of the third quarter, Pressure had cash and cash equivalents totaling $41,939.

Following the recent achievement of several milestones, including the launch of the next-generation Barocycler 2320Extreme mass spectrometry protein sample prep instrument, Pressure is now focused on expanding and enhancing its "current financial, operational, and technical capabilities, and … [finding] additional ways to help ensure that our progress is seen and understood by the worldwide financial and investor communities," Pressure President and CEO Richard Schumacher said in a statement. 

Doing so, he added, "may include, among other things, additions to staff, independent agents, distributors, and consultants focused primarily in sales and marketing."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.